Study of risperidone began in the late s and it was approved for sale in the United States in Risperidone is mainly used for the risperidone (risperdal) 1mg tablet of schizophrenia, bipolar disorder, ...

BRIDGEWATER, N.J. — Ajanta Pharma USA on Friday announced the launch of risperidone tablets (0.25-mg, 0.5-mg, 1-mg, 2-mg, 3-mg and 4-mg), the generic version of Risperdal. The drug is used to treat ...

The U.S. Food and Drug Administration approved the first generic versions of Risperdal (risperidone) tablets. Risperdal is an antipsychotic drug used for the treatment of schizophrenia, bipolar ...

Risperidone was the first drug approved to control explosive and aggressive behavior in children with autism. The smallest amount you can measure with the pipette is 0. The dose was administered once ...

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the publication of efficacy ...

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyndra Therapeutics ®, a clinical-stage biopharmaceutical company, today announced positive data from the STARLYNG-1 (LYN-005-C-301) study, comparing the ...

A novel once-weekly capsule loaded with the antipsychotic risperidone, LYN-005, provided similar bioavailability and symptom control as daily doses of the drug in a phase 3 trial of patients with ...

Risperidone for Extended-Release Injectable Suspension is used for the treatment of schizophrenia on its own or in combination with lithium or valproate for the maintenance treatment of Bipolar I ...

PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS--(BUSINESS WIRE)-- Regulatory News: Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell ...

J&J to Pay $2.2B Settlement to End Risperdal Probes New Brunswick, N.J.-based Johnson & Johnson has agreed to pay up to $2.2 billion to settle U.S. investigations and lawsuits regarding its marketing ...

Luye Pharma has entered a space targeted by Johnson & Johnson and Teva, securing FDA approval for its extended-release injectable formulation of risperidone in schizophrenia and bipolar I disorder.